Pharmaessentia USA Corporation

Biopharmaceutical company that develops treatments for myeloproliferative neoplasms, more

Based in MA

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $160K in lobbying spend across 8 quarterly filings, Pharmaessentia USA Corporation is an active lobbying client. Their lobbying covers 1 issue area. Active from 2024 to 2025.

$160K
Total Spend
2
Years Active
1
Firms Hired
5
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2024$160K
2025$0

Issues Lobbied

Medicare/Medicaid

Lobbying Firms

Arnold & Porter Kaye Scholer LLP

Lobbyists

Sonja NesbitMickayla StogsdillBobby McmillinEugenia PiersonLeigh Fairley

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid

  • •Issues related to implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
  • •Issues related to implementation of the Inflation Reduction Act (IRA, P.L. 117-169).

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

Akebia Therapeutics, INC.
$9.8M total spend
Ardelyx, INC.
$9.4M total spend
Sage Therapeutics
$4.8M total spend
Organogenesis INC.
$4.0M total spend
Lantheus Holdings, INC.
$3.9M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.